Biologics

#Biologics #Collaboration #Ginkgo Bioworks #Merck

Ginkgo and Merck collaborate to improve biologic manufacturing 

Ginkgo Bioworks and Merck have collaborated to improve the production of biologics.  Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterisation and process optimisation to improve production efficiency and increase yields.   “We’re thrilled to leverage our platform to… Read More

#News

Biologics research
#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

Guide: Assessing thermal stability with nanoDSF

A new Guide ‘The biologics researcher’s mini-guide to screening candidates with nanoDSF’ is now available from NanoTemper. Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read More

#News

#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

The biologics researcher’s mini-guide to screening candidates with nanoDSF

Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read this mini-guide to learn: How nanoDSF uses your protein’s intrinsic fluorescence to determine its melting temperature, Tm and onset… Read More

#Intelligence #Resources

#Biologics #Biology #Biotechnology #Drug development #Therapeutics

Next-generation pipeline for treating mast cell driven diseases 

Granular Therapeutics, a UK-based biotech company specialising in precision biologic therapies for treating mast cell driven disorders, announced clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies.  Granular Therapeutics has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares… Read More

#News

#Biologics #Cancer research #Cancer treatment #Immunology #Oncology

Biologics and living drugs: entering a new era of cancer treatment

This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and… Read More

#Cancer Research #Exclusive Content

Cell culture media
#Biologics #Bioproduction #Cell and gene therapy #Cell therapy #Life sciences #Manufacturing

Fujifilm expands cell culture media manufacturing

Fujifilm Corporation has announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.  The new site will be operated by Fujifilm Irvine Scientific, a manufacturer of cell culture solutions for life science research, bioproduction, cell therapy… Read More

#News

#Biologics #Biotechnology #Funding #Seed funding #Therapeutics

How will $41 million be used to fight chronic and age-related diseases? 

Juvena Therapeutics, a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics… Read More

#Business & Investment #News

#Biologics #Cell and gene therapy #Clinical research #Comment #FDA #Regulatory

The significance of FDA industry guidance on cell and gene therapies 

On 4 November 2022, the FDA’s Center for Biologics Evaluation and Research released guidance for the industry on studying multiple versions of a cellular or gene therapy (CGT) product in an early-phase clinical trial in a single disease1. This guidance finalises the draft guidance of the same title dated September… Read More

#Exclusive Content #Opinion #Regulatory

#Antibodies #Biologics #Data #Drug design #Exscientia

Exscientia extends capabilities beyond small molecules 

Throughout 2022, Exscientia has progressed AI-driven capabilities for virtual biologics design, such as human antibodies, and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies.   Context  Current approaches to optimise antibodies, even those that use machine learning, still… Read More

#News

#Biologics #Life sciences #Pharmaceuticals

Podcast: The changing drug discovery landscape

This is the latest episode of the free DDW podcast, “What does the changing drug discovery and development landscape mean for the future?”. It covers three articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas. They are called “The… Read More

#News

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Interview #Oncology #PharmEnable

Sitting down with… PharmEnable

Listen to this article on the DDW podcast: Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside. RA: How is Pharmenable aiming to replicate the specificity of biologics… Read More

#Exclusive Content

mRNA vaccines
#Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #mRNA #Vaccines

Preparing for new-era drug modalities with technology 

Listen to this article on the DDW podcast: Samsung Biologics’ Senior Vice President, James Park, explores the opportunities emerging for CDMOs to support mRNA developers as they explore new therapeutic areas for patients.  Prior to the pandemic, messenger RNA (mRNA) drug development was niche and predominantly pointed at different disease targets,… Read More

#Exclusive Content

#Biologics #Bioproduction #Bioseparation #Cell and gene therapy #Purification technology

How to achieve greener, faster and more cost-effective bioprocessing workflows 

Astrea Bioseparations has launched its Nereus LentiHERO lentiviral vector (LVV) purification technology commercially. Incorporating AstreAdept, the company’s proprietary nanofiber material, this solution has been created to address the challenges associated with purifying the large and fragile products used in cell and gene therapy. AstreAdept is a proprietary bioseparations material that… Read More

#News

Crohn's disease
#Biologics #Crohn's disease #Exclusive Enteral Nutrition #Gut microbiome #Nutrition

Potential new treatment for Crohn’s disease patients in Scotland

A new clinical trial, led by the University of Glasgow and NHS Greater Glasgow and Clyde (NHSGGC), hopes to improve treatment options for patients with Crohn’s disease.   The BIOPIC (BIOlogics and Partial enteral nutrition In adults with active ileocolonic Crohn’s disease) study, which is in collaboration with hospitals… Read More

#News

#Biologics #Cell and gene therapy #Malaria #Manufacturing #Oncology

This week in drug discovery (26-30 September)

This week in drug discovery (26-30 September) News round-up by DDW Editor Reece Armstrong. An interesting week across the board for the pharma sector with the first biologic for severe asthma approved in the EU. Elsewhere researchers have discovered new ways of  identifying cancer cells and a manufacturing system could… Read More

#News

Asthma inhaler
#Asthma #Biologics

First and only biologic approved in the EU in patients with severe asthma 

AstraZeneca’s Tezspire (tezepelumab) has been approved in the European Union as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.  The approval by the European Commission was based on results… Read More

#News